您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > (±)-Talinolol
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
(±)-Talinolol
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
(±)-Talinolol图片
CAS NO:57460-41-0
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
β1-selective adrenoceptor antagonist
Cas No.57460-41-0
别名他林洛尔,Cordanum
化学名N-cyclohexyl-N'-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-urea
Canonical SMILESO=C(NC1CCCCC1)NC2=CC=C(OCC(O)CNC(C)(C)C)C=C2
分子式C20H33N3O3
分子量363.5
溶解度≤10mg/ml in ethanol;15mg/ml in DMSO;30mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

(±)-Talinolol is a selective β1 adrenoceptor antagonist with cardioprotective and antihypertensive activity.

β adrenoceptor antagonist is a class of medications that are particularly used to manage cardiac arrhythmias, and to protect the heart from a second heart attack after a first heart attack.

By blocking β1-adrenergic receptors, (±)-talinolol delays the conduction of stimuli in the AV node, reduces the sino-atrial conduction time, and impedes the sinus node automaticity [1]. Pharmacokinetic data of the time course of plasma concentrations following intravenous infusion of 30 mg (±)-Talinolol revealed that the peak serum concentration (Cmax), the area under the serum concentration-time curve (AUC), and terminal elimination halflife (t1/2) were 631±95 ng/ml, 1433±153 ng×h/ml, and 10.6±3.3 h, respectively. Pharmacokinetic data of the time course of plasma concentrations following oral administration of 50 mg (±)-Talinolol revealed that the Cmax, the AUC, and the t1/2 were 168±67 ng/ml, 1321±382 ng×h/ml, and 11.9±2.4 h, respectively [2].

References:
[1] Abmann I.  The actions of talinolol, a β1-selective beta blocker, in cardiac arrhythmia and acute myocardial infarction[J]. Current Medical Research and Opinion, 2008, 13(6): 325-342.
[2] Trausch B, Oertel R, Richter K, et al.  Disposition and bioavailability of the β1‐adrenoceptor antagonist talinolol in man[J]. Biopharmaceutics & Drug Disposition, 1995, 16(5): 403-414.